The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase (Ph) I/II study of investigational Aurora A kinase (AAK) inhibitor MLN8237 (alisertib): Updated ph II results in patients (pts) with small cell lung cancer (SCLC), non-SCLC (NSCLC), breast cancer (BrC), head and neck squamous cell carcinoma (HNSCC), and gastroesophageal cancer (GE).
Bohuslav Melichar
Consultant or Advisory Role - Roche
Honoraria - Novartis; Roche
Antoine Adenis
Consultant or Advisory Role - Amgen; Bayer; Roche; Sanofi
Honoraria - Amgen; Bayer; Roche
Libor Havel
No relevant relationships to disclose
Albert C. Lockhart
Research Funding - Millennium
Jaafar Bennouna
Consultant or Advisory Role - Amgen; Roche; Sanofi
Honoraria - Amgen
Claudia Schusterbauer
Employment or Leadership Position - Millennium
Claudio Dansky Ullmann
Employment or Leadership Position - Millennium
Bin Zhang
Employment or Leadership Position - Millennium
Stock Ownership - Takeda
Ely Benaim
Employment or Leadership Position - Millennium
Stock Ownership - Takeda
Elizabeth Claire Dees
Research Funding - Millennium